ArticleJournal of translational medicine2011
Promoter methylation and downregulation of SLC22A18 are associated with the development and progression of human glioma.
Article in Journal of translational medicine, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 38 citations in OpenAlex.
- The effect of genetic variants of SLC22A18 on proliferation, migration, and invasion of colon cancer cells.Scientific reports · 2024Article
- Expression of SLC22A18 regulates oxaliplatin resistance by modulating the ERK pathway in colorectal cancer.American journal of cancer research · 2022Article
- The Roles of ImprintedCancers · 2020Article
- Novel long noncoding RNA OTUD6B-AS1 indicates poor prognosis and inhibits clear cell renal cell carcinoma proliferation via the Wnt/β-catenin signaling pathway.Molecular cancer · 2019Article
- Silencing SATB1 overcomes temozolomide resistance by downregulating MGMT expression and upregulating SLC22A18 expression in human glioblastoma cells.Cancer gene therapy · 2018Article
- Potential Epigenetic-Based Therapeutic Targets for Glioma.Frontiers in molecular neuroscience · 2018Review
- Hypermethylation of MEG3 promoter correlates with inactivation of MEG3 and poor prognosis in patients with retinoblastoma.Journal of translational medicine · 2017Article
- Effects of resveratrol and methoxyamine on the radiosensitivity of iododeoxyuridine in U87MG glioblastoma cell line.Experimental biology and medicine (Maywood, N.J.) · 2016Article
- Expression and prognostic value of the aldehyde dehydrogenase 1 (ALDH1) and N-myc downstream regulated gene 2 (NDRG2) as potential markers in human astrocytomas.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2016Article
- SLC transporters as a novel class of tumour suppressors: identity, function and molecular mechanisms.The Biochemical journal · 2016Review
- Characterization of SLC22A18 as a tumor suppressor and novel biomarker in colorectal cancer.Oncotarget · 2015Article
- In vitro and in vivo radiosensitization of human glioma U251 cells induced by upregulated expression of SLC22A18.Cancer gene therapy · 2014Article
- Clinical value of chromosome arms 19q and 11p losses in low-grade gliomas.Neuro-oncology · 2014Article
- Inhibition of human glioma U251 cells growth in vitro and in vivo by hydroxyapatite nanoparticle-assisted delivery of short hairpin RNAs against SATB1.Molecular biology reports · 2014Article
- DNA methylation characteristics of primary melanomas with distinct biological behaviour.PloS one · 2014Article
- Dysregulated methylation at imprinted genes in prostate tumor tissue detected by methylation microarray.BMC urology · 2013Article
- In vitro and in vivo radiosensitization induced by hydroxyapatite nanoparticles.Neuro-oncology · 2013Article
- Predictive value of the SLC22A18 protein expression in glioblastoma patients receiving temozolomide therapy.Journal of translational medicine · 2013Article
- DNA methylation as an adjunct to histopathology to detect prevalent, inconspicuous dysplasia and early-stage neoplasia in Barrett's esophagus.Clinical cancer research : an official journal of the American Association for Cancer Research · 2013Article
- Different involvement of promoter methylation in the expression of organic cation/carnitine transporter 2 (OCTN2) in cancer cell lines.PloS one · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDownregulation of the putative tumor suppressor gene SLC22A18 has been reported in a number of human cancers. The aim of this study was to investigate the relationship between SLC22A18 downregulation, promoter methylation and the development and progression of human glioma.
methodSLC22A18 expression and promoter methylation was examined in human gliomas and the adjacent normal tissues. U251 glioma cells stably overexpressing SLC22A18 were generated to investigate the effect of SLC22A18 on cell growth and adherence in vitro using the methyl thiazole tetrazolium assay. Apoptosis was quantified using flow cytometry and the growth of SLC22A18 overexpressing U251 cells was measured in an in vivo xenograft model.
resultsSLC22A18 protein expression is significantly decreased in human gliomas compared to the adjacent normal brain tissues. SLC22A18 protein expression is significantly lower in gliomas which recurred within six months after surgery than gliomas which did not recur within six months. SLC22A18 promoter methylation was detected in 50% of the gliomas, but not in the adjacent normal tissues of any patient. SLC22A18 expression was significantly decreased in gliomas with SLC22A18 promoter methylation, compared to gliomas without methylation. The SLC22A18 promoter is methylated in U251 cells and treatment with the demethylating agent 5-aza-2-deoxycytidine increased SLC22A18 expression and reduced cell proliferation. Stable overexpression of SLC22A18 inhibited growth and adherence, induced apoptosis in vitro and reduced in vivo tumor growth of U251 cells.
conclusionSLC22A18 downregulation via promoter methylation is associated with the development and progression of glioma, suggesting that SLC22A18 is an important tumor suppressor in glioma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.